StreetAlpha.app
Home › Stocks › GH

Guardant Health, Inc. (GH)

Healthcare
$145.83
▲ +0.16%
LAST CLOSE · NOV 20

Guardant Health offers blood and tissue tests for cancer screening, treatment selection and disease monitoring. It last closed at $145.83 on Nov 20, up 0.16% on the day. The next earnings report for GH is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, GH reported EPS of -$0.93 on revenue of $361.0M, with revenue up 36.1% from a year ago. Over its last 8 reports the stock moved an average of 7.2% the session after earnings. Over the last 12 months GH insiders bought $78K of stock on the open market and sold $173.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is GH in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GH.

Key Stats

Last 12 months
Results
Revenue
$1.3B
+41.7% vs a year ago
Net income
−$485.1M
−37.9% margin
EPS (diluted)
−$3.68
Free cash flow
−$232.1M
−18.2% margin
Valuation
Market cap
$19.7B
135.3M shares
P/E
–
No P/E while losing money
Price to sales
15.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.0B
At Sep 30
Debt
$1.5B
At Sep 30
Shareholder equity
−$275.9M
Shares outstanding
135.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $373.7M$373.7MFY2021FY2022: $449.5M$449.5MFY2022FY2023: $563.9M$563.9MFY2023FY2024: $739.0M$739.0MFY2024FY2025: $982.0M$982.0MFY2025

From GH's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.93
Quarter ended Sep 2026
Year ago EPS
-$0.74
Same quarter last year
Revenue
$361.0M
+36.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.90Dec '24Mar 2025: -$0.77Mar '25Jun 2025: -$0.80Jun '25Sep 2025: -$0.74Sep '25Dec 2025: -$1.00Dec '25Mar 2026: -$0.85Mar '26Jun 2026: -$0.90Jun '26Sep 2026: -$0.93Sep '26Latest -$0.93
Revenue by quarter
Dec 2024: $201.8MDec '24Mar 2025: $203.5MMar '25Jun 2025: $232.1MJun '25Sep 2025: $265.2MSep '25Dec 2025: $281.3MDec '25Mar 2026: $301.7MMar '26Jun 2026: $335.0MJun '26Sep 2026: $361.0MSep '26Latest $361.0M
How GH moved after its last 8 reports
Average move the session after a report ±7.2%
Nov 5, 2026After the close−1.7%
Jul 30, 2026After the close+6.3%
May 7, 2026After the close+3.7%
Feb 19, 2026After the close−3.1%
Jan 12, 2026Time not announced−2.4%
Oct 29, 2025After the close+27.9%
Jul 30, 2025After the close−9.3%
Apr 30, 2025After the close+3.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on GHStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on GH: 0 upgrades, 0 downgrades, 0 initiations
StephensReiterated
Nov 21Overweight 

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on GH
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on GH

Technical Analysis

GH · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 10% below its 20 day and 15% below its 50 day average. It is 8% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot at $145.03, and the nearest resistance the Pivot R1 at $149.06.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 6.4%/day
Key levels
$191.0552 week high+31.0%
$167.0950 day average+14.6%
$163.47100 day average+12.1%
$163.39Swing high (Nov 11)+12.0%
$160.8020 day average+10.3%
$149.06Pivot R1+2.2%
$145.83Last close
$145.03Pivot−0.5%
$144.85Swing low (Jul 21)−0.7%
$141.80Pivot S1−2.8%
$133.67200 day average−8.3%
$74.5552 week low−48.9%
Indicators
RSI (14)36.79Weak, oversold below 30Neutral
MACD-6.54Below its signal lineBearish
Stochastic20.4Middle of its rangeNeutral
ADX (14)21.1Weak trend
Williams %R-77.6Oversold below −80, overbought above −20Neutral
CCI (20)-87.3Oversold below −100, overbought above 100Neutral
Rate of change−3.3%Change over 10 sessionsBearish
ATR (14)$9.35Typical daily range, 6.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for GH

What happened before

See how GH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow GH usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How GH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for GHHow many large options trades hit GH, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

GH Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲390 buying vs 276 selling
  • ▼Held by funds -4.6 pts
  • ▲Funds holding +71
  • ▼Superinvestors: 2 added, 3 cut
  • ▼Put/call 1.87 to 5.52
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding682611+11.6%
In funds' top 102219+15.8%
Held by funds99.0%103.6%−4.6 pts
New / increased139 / 251157 / 202+8.6%
Reduced / sold out209 / 67179 / 45+23.2%
Put/call ratio5.521.87+195.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GH institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

GH Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$78K1 buy · 1 insider
Sold$173.5M56 sales · 15 insiders
47% of the selling was under pre-arranged trading plans.
2025-12 sold $43.7M2026-01 sold $2.1M2026-03 sold $4.2M2026-04 sold $365K2026-05 sold $35.4M2026-06 bought $78K2026-06 sold $56.4M2026-07 sold $19K2026-08 sold $27.3M2026-09 sold $3.3M2026-10 sold $30K2026-11 sold $575KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Terilyn J. MonroeChief People OfficerSale plan3,842$142.41$547K
Nov 16Alex M Azar IIDirectorSale plan69$149.56$10K
Nov 16Musa TariqDirectorSale plan116$149.56$17K
Oct 16Musa TariqDirectorSale plan116$165.88$19K
Oct 14Alex M Azar IIDirectorSale plan69$159.89$11K
Sep 16Alex M Azar IIDirectorSale plan826$175.00$145K
Every insider buy and sale for GH over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See GH insider trades →

From SEC Form 4 filings by GH's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GH is in one of them and how their past GH trades turned out.

GH in the AI portfolios
Loading…

GH News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GH in an article yet. Here's the latest on the wider market.

GH in the news

GH Congress Trades

All congress trades →
Trades, 12 months
2
Buys
2
100%
Sells
0
0%
People
2
Last filed Oct 19
Who traded GH · since 2020
Latest 5 filings of 12
$15K – $50KTraded Sep 28, 2026Filed Oct 19, 2026
$1K – $15KTraded Nov 21, 2025Filed Dec 1, 2025
$1K – $15KTraded Feb 28, 2022Filed Mar 3, 2022
$1K – $15KTraded Jan 13, 2022Filed Feb 1, 2022
$1K – $15KTraded Dec 22, 2021Filed Jan 1, 2022
PersonTypeAmountTradedFiledDelay
Jonathan JacksonD · ILBuy$15K – $50KSep 28, 2026Oct 19, 202621 d
Sheldon WhitehouseD · RIBuy$1K – $15KNov 21, 2025Dec 1, 202510 d
Don BeyerD · VASell$1K – $15KFeb 28, 2022Mar 3, 20223 d
Don BeyerD · VASell$1K – $15KJan 13, 2022Feb 1, 202219 d
Don BeyerD · VASell$1K – $15KDec 22, 2021Jan 1, 202210 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Guardant Health

Guardant Health is a precision oncology company based in Palo Alto, California. It offers blood and tissue tests that help doctors choose treatments for patients with advanced cancer, monitor for residual or returning disease after early stage treatment, and screen adults for colorectal cancer. The company also provides its tests and AI-based data analytics tools to biopharmaceutical companies running clinical studies and drug development. Its customers include oncologists, physicians, health systems and drug developers.

Headquarters
Palo Alto, CA